To investigate the clinicopathological features of pure red cell aplasia (PRCA) linked to immune checkpoint inhibitors (ICIs).
Analysis of clinical records from cancer patients receiving ICIs.
Identification of cases of PRCA occurring post-treatment.
Evaluation of intervention strategies based on early diagnosis.
PRCA commonly emerges about 3 months after initiation of ICI treatment.
Early diagnosis leads to improved outcomes for affected patients.
Favorable responses to timely interventions were noted.
Abstract
PRCA induced by ICIs is a rare immune-related adverse event that typically occurs around 3 months after treatment. Early identification and appropriate intervention can lead to favorable outcomes.